Eltrombopag (75mg) does not induce photosensitivity: Results of a clinical pharmacology trial

Photodermatology Photoimmunology and Photomedicine

Volumn 26, Issue 5, 2010, Pages 243-249

  Bowen, Carolyn J ^a   Lobb, Kathryn M ^a   Park, Jung Wook ^a   Sanderson, Brian ^b   Ferguson, James ^c  

^a GLAXOSMITHKLINE   (United States)

^b Chiltern Limited   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Eltrombopag; Photosensitivity; Phototoxic index; Thrombocytopenia

Indexed keywords

CIPROFLOXACIN; ELTROMBOPAG; PLACEBO; BENZOIC ACID DERIVATIVE; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; THROMBOPOIETIN RECEPTOR;

ADULT; ALLERGY; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSPEPSIA; EOSINOPHILIA; ERYTHEMA; FEMALE; HEADACHE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; MALE; MIGRAINE; NIGHTMARE; NORMAL HUMAN; PERIPHERAL EDEMA; PHOSPHOKINASE BLOOD LEVEL; PHOTOSENSITIVITY; PHOTOSENSITIZATION; PHOTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SOLAR RADIATION; SPECTRAL SENSITIVITY; TACHYCARDIA; THROMBOCYTHEMIA; THROMBOCYTOPENIA; ULTRAVIOLET A RADIATION; ULTRAVIOLET RADIATION; CONTACT DERMATITIS; DRUG POTENTIATION; MIDDLE AGED; NONPARAMETRIC TEST;

ADULT; BENZOIC ACIDS; DERMATITIS, PHOTOTOXIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDRAZINES; MALE; MIDDLE AGED; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; STATISTICS, NONPARAMETRIC; ULTRAVIOLET RAYS; YOUNG ADULT;

EID: 77956489314     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2010.00538.x     Document Type: Article

References (11)

1. Jenkins JM, Williams D, Deng Y. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007, 109:4739-4741.
2. Bussel JB, Cheng G, Saleh MN. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357:2237-2247.
3. McHutchison JG, Dusheiko G, Shiffman ML. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007, 357:2227-2236.
4. Bussel JB, Provan D, Shamsi T. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:641-648.
5. Erickson-Miller CL, Delorme E, Tian SS. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009, 27:424-430.
6. Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009, 37((9)):1030-1037.
7. Ferguson J, McEwen J, Al-Ajmi H, Purkins L, Colman PJ, Willavize SA. A comparison of the photosensitizing potential of trovafloxacin with that of other quinolones in healthy subjects. J Antimicrob Chemother 2000, 45:503-509.
8. Man I, Murphy J, Ferguson J. Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. J Antimicrob Chemother 1999, 43((Suppl. B)):77-82.
9. Ferguson J, Johnson BE. Clinical and laboratory studies of the photosensitizing potential of norfloxacin, a 4-quinolone broad-spectrum antibiotic. Br J Dermatol 1993, 128:285-295.
10. Ferguson J, Johnson BE. Photosensitivity due to retinoids: clinical and laboratory studies. Br J Dermatol 1986, 115:275-283.
11. Hollander M, Wolfe DA. Nonparametric statistical methods 1973, 75-82. New York, Wiley